We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+9.98%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$846M
AUM Growth
-$143M
Cap. Flow
-$121M
Cap. Flow %
-14.33%
Top 10 Hldgs %
70.39%
Holding
52
New
24
Increased
5
Reduced
10
Closed
6

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$47.4M
2
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$36.8M
3
TGTX icon
TG Therapeutics
TGTX
+$19.2M
4
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$18.7M
5
LRMR icon
Larimar Therapeutics
LRMR
+$13.8M

Top Sells

Rank Stock Value
1
ACHN
Achillion Pharmaceuticals
ACHN
+$147M
2
ENTA icon
Enanta Pharmaceuticals
ENTA
+$51.4M
3
RPRX
Repros Therapeutics Inc.
RPRX
+$21.1M
4
DYAX
DYAX CORPORATION
DYAX
+$21.1M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$20.5M

Sector Composition

Rank Sector Weight
1 Healthcare 49.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
51
DELISTED
Immunomedics Inc
IMMU
– –
-1,000,000
Closed -$3.65M
RPRX
52
DELISTED
Repros Therapeutics Inc.
RPRX
– –
-1,219,381
Closed -$21.1M
1 2
3

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2014 Portfolio in Review

As of Q3 2014, RA Capital Management held 52 positions worth $846M, down 14% from $989M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

RA Capital Management withdrew a net $121M in Q3 2014, closing 6 positions and reducing 10 holdings. Its most notable exit was Repros Therapeutics Inc., an estimated $21.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 60% a quarter earlier.

Against the trend, RA Capital Management opened a new position in AVANIR PHARMACEUTICALS, INC CL A worth $64.2M.

  • RA Capital Management's largest Q3 2014 buy was AVANIR PHARMACEUTICALS, INC CL A: 5,386,700 shares worth $64.2M.
  • RA Capital Management added most to BioCryst Pharmaceuticals in Q3 2014, an estimated $47.4M increase.
  • RA Capital Management's biggest Q3 2014 reduction was Achillion Pharmaceuticals, cutting an estimated $147M.
  • RA Capital Management fully exited Repros Therapeutics Inc. in Q3 2014, selling an estimated $21.1M.
  • RA Capital Management's ten largest holdings make up 70% of its $846M portfolio in Q3 2014.
  • RA Capital Management opened 24 new positions and closed 6 in Q3 2014.
  • RA Capital Management's portfolio value fell 14% quarter-over-quarter to $846M.

Based on RA Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.